Introduction {#s1}
============

About 10% of all breast cancers are of monogenic origin [@pone.0037432-Meindl1]. The most prevalent entity is Hereditary Breast and Ovarian Cancer (HBOC), an autosomal dominant disease with incomplete penetrance. The two high-penetrance genes most commonly mutated in HBOC are the tumor suppressor genes *BRCA1* and *BRCA2* (*breast cancer, early onset 1* and *2*). The *BRCA1* gene, localized at 17q21, and *BRCA2*, at 13q12, have long coding sequences (5589 and 10254 nt for *BRCA1* and *BRCA2*, respectively) and are essential components of the double-strand break repair by homologous recombination system [@pone.0037432-Narod1]. Almost 3500 deleterious mutations in these genes have been found in all the coding sequence [@pone.0037432-Petrucelli1]. Furthermore *BRCA1* and *BRCA2* mutation carriers are also at increased risk of fallopian tubes, pancreatic, prostate and endometrial cancer [@pone.0037432-Medeiros1]--[@pone.0037432-Edwards1].

The molecular diagnosis of mutations in *BRCA* genes implies high degree of clinical suspicion based principally in history of familial BRCA-related cancers in first- or second-degree relatives, age of presentation and tumor characteristics (morphological, immunohistochemical and molecular features) [@pone.0037432-Pruthi1]. For patients with a BRCA mutation, current clinical alternatives include breast and ovarian screening, prophylactic surgery, and chemoprevention [@pone.0037432-Paradiso1]. The approach extends to their family in order to identify other members at risk to allow the genetic advice, screening and/or predictive testing [@pone.0037432-Clark1].

Unfortunately, genetic testing for mutations in *BRCA1* and *BRCA2* is not always available in public institutions in developing countries due to its high cost and limitations in infrastructure. As BRCA genes have long coding sequences and lack mutation hot spots, the current strategies for BRCA genotyping typically include a first step to detect occurring mutations by protein truncation test (PTT), denaturing high-performance liquid chromatography (dHPLC), denaturing gradient gel electrophoresis (DGGE) or high-resolution melting curve analysis (HRMCA); and a final step to determine the mutation by Sanger sequencing [@pone.0037432-Gerhardus1]. These approaches are laborious, expensive and time consuming, and could be substituted by high throughput, cost efficient testing methods such as massively parallel sequencing [@pone.0037432-Wang1], [@pone.0037432-DeLeeneer1].

In this work we used massive parallel pyrosequencing to screen for mutations in the complete coding regions and splice sites of *BRCA* genes in Mexican women. We studied 39 patients with breast and/or ovary cancer and with history of familial cancer and with early-onset breast cancer, suggestive for *BRCA* mutations. We found 4 pathogenic mutations, of which 3 have not been described. We also identified 16 missense mutations with unknown deleterious effects. In addition, by a directed sequencing strategy, we evaluated the presence of the deleterious mutations in the family members of the patients. Also, we identified family members with the mutations and with no clinical manifestations of cancer. These patients began clinical management (that includes follow-up and prophylactic measures). This work illustrates how new sequencing technology for screening of mutations in *BRCA* genes impacts the familial health scenario and can be conducted as part of the genetic approach for patients with familial cancer in public health care institutions.

Methods {#s2}
=======

Patients {#s2a}
--------

A total of 39 patients were screened. Thirty-five female patients with breast and/or ovarian cancer and with two or more first- or second-degree relatives with tumors associated with *BRCA* mutations were studied. Two male patients with breast cancer were included. All patients were clinically approached and a three-generation genealogy of each family was made. Two patients without familial cancer history, one with early-onset (age of diagnosis: 28) breast cancer and one with breast and ovarian cancer, suggestive for *BRCA* mutations, were also included. Patients were fully informed about the study and gave their written consent. The protocol was approved by the Institutional Review Boards of the National Cancer Institute of Mexico (<http://www.incan.edu.mx/>) and carried out in accordance with the Declaration of Helsinki, good clinical practices, and local ethical and legal requirements.

DNA isolation {#s2b}
-------------

Genomic DNA was isolated of peripheral blood with the Magna Pure System (Roche) following manufacturer instructions. The integrity of the material was verified by agarose electrophoresis. Sample quantification was done with the Quant-it Picogreen kit (Invitrogen) in a QuantiFluor Fluorometer (Promega).

Pyrosequencing {#s2c}
--------------

A Sequencing Master library of amplicons covering all the coding exons and splice sites of *BRCA1* and *BRCA2* was produced for each patient using the BRCAMASTR kit (Multiplicom) following manufacturer instructions. Briefly, 50 ng of gDNA were used as template in each of 12 multiplex PCR reactions for each patient. These reactions amplified the complete exonic and splice sites of *BRCA1* and *BRCA2*. A 1∶1000 dilution of the purified PCR products were re-amplified using molecular identification (MID) adaptors for each patient. A BRCA amplicon library of each patient was generated and equivalent concentrations of the libraries were pooled to generate a Sequencing Master library. Pyrosequencing of the Master libraries were done in the sense and anti-sense strands with the 454 GS Junior (Roche) technology. Data analysis was done with the GS Amplicon Variant Analyzer software (Roche) comparing against genomic references NG_005905 and NG_012772 for *BRCA1* and *BRCA2*, respectively. The cDNA references utilized were NM_007294 and NM_000059 for *BRCA1* and *BRCA2*, respectively. The nomenclature used is based on the cDNA sequence and is according to Human Genome Variation Society (<http://www.hgvs.org/>). All the deleterious mutations found were verified by Sanger sequencing of original patient blood DNA and by restriction analysis when possible. The putative functional effects of missense variants were analyzed *in silico* with PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>).

Restriction analysis {#s2d}
--------------------

The presence of the mutation c.3124_3133delAGCAATATTA found in patient 11 was verified by restriction analysis of the PCR product (554 pb) amplified with the primers BRCA1-11.1F: TCAGAGGCAACGAAACTGGACTCA and BRCA1-11.1R: CAGCCTATGGGAAGTAGTCATGCA. The mutated allele lacks the restriction site for *Ssp*I (AATATT) and is not cleaved by this enzyme, while the wild-type allele is cleaved in two fragments (257 and 297 pb). 500 ng of PCR products were digested with 1 U of *Ssp*I (Fermentas) at 37°C for 4 h in 20 uL. Ten uL of the reactions were visualized in 1.5% agarose gels.

Results {#s3}
=======

To analyze the performance of the amplicon strategy for the sequencing of BRCA genes we carried out an evaluation run with 6 patients\' samples, of which 4 had previously identified mutations and 2 were negative controls [@pone.0037432-VidalMilln1]. We used three inclusion criteria to accept valid mutated sequences: 1) mutation found in forward and reverse sequences, 2) at least 30% of sequences with the mutations and 3) at least 20X of sequence coverage of the amplicons with the mutation. Also we defined three exclusion criteria: 1) mutations detected in an homopolymeric tract of ≥6, 2) mutations found in the last nucleotide of the sequence and with frequencies of less than 30% and 3) quality score lower than 20 in forward and reverse reads. Similar criteria have been described elsewhere [@pone.0037432-DeLeeneer1]. As seen in [table 1](#pone-0037432-t001){ref-type="table"}, we detected all the deleterious mutations in the positive controls and no pathogenic variants were found in the negative controls. In the mutations observed the minimal and maximal coverage was 41 and 485 reads per nucleotide, respectively. Also in this control experiment more than 70% of all the reads across the whole exon and splice sites had a quality score (Q) ranging from 36 to 40 (highest score), and low quality reads with Q\>20 were less than 10% ([Fig. 1](#pone-0037432-g001){ref-type="fig"}). As expected, we observed that the majority of these low quality reads were in homopolymeric tracts, especially of \>6 bases. Although present, these homopolymeric sequences are a negligible number of the total reads ([Fig. 2](#pone-0037432-g002){ref-type="fig"}). With this analysis we concluded that the strategy used was robust and suitable for its application in the screening of BRCA mutations in patients\' samples.

![Quality of the sequencing runs.\
The percentages of the reads with their associated quality numbers of all runs are plotted.](pone.0037432.g001){#pone-0037432-g001}

![Distribution of homopolymeric tracts across the reads.\
The base number signals are plotted against the sequence reads of the control run.](pone.0037432.g002){#pone-0037432-g002}

10.1371/journal.pone.0037432.t001

###### Evaluation of the methodological strategy for the detection of BRCA mutations.

![](pone.0037432.t001){#pone-0037432-t001-1}

  Sample           Gene     Deleterious Mutation   Type of mutation[a](#nt102){ref-type="table-fn"}   Position (aa)   Stop codón position (aa)   Coverage[1](#nt101){ref-type="table-fn"}   Clinical relevance   BIC reported                                    Reference
  -------------- --------- ---------------------- -------------------------------------------------- --------------- -------------------------- ------------------------------------------ -------------------- -------------- ------------------------------------------------------------------------------
  Control (+)1    *BRCA1*    c.4065_4068delTCAA                           F                               1355                  1364                                41                             Yes               Yes        [@pone.0037432-VidalMilln1], [@pone.0037432-Liede1]--[@pone.0037432-Saxena1]
  Control (+)2    *BRCA2*    c.2808_2811delACAA                           F                                936                  958                                459                             Yes               Yes                                  [@pone.0037432-Salazar1]
  Control (+)3    *BRCA2*        c.9382C\>T                               S                               3128                  3128                               485                             Yes               Yes                       [@pone.0037432-Simard1], [@pone.0037432-Borg1]
  Control (−)1      \-         None detected                              \-                               \-                    \-                                 \-                              \-                \-                                             \-
  Control (−)2      \-         None detected                              \-                               \-                    \-                                 \-                              \-                \-                                             \-

Number of reads per nucleotide.

Types of mutations: F: frameshift; S: stop.

We screened for mutations in the whole coding sequence of BRCA genes in 39 patients with early-onset breast and ovarian tumors and/or with familial history of cancer, suggestive for *BRCA* mutations, as determined by our Clinic of Genetics. The main clinical characteristics of the patients are listed in [table 2](#pone-0037432-t002){ref-type="table"} and [3](#pone-0037432-t003){ref-type="table"}. After the pyrosequencing analysis and careful examination of the reads with our criteria of inclusion and exclusion, we found 4 mutations in the BRCA genes (c.2805_2808delAGAT and c.3124_3133delAGCAATATTA in *BRCA1*; c.2639_2640delTG and c.5114_5117delTAAA in *BRCA2*). All mutations were predicted to be deleterious because each generated a stop codon in the open reading frame ([Table 4](#pone-0037432-t004){ref-type="table"}). These pathogenic mutations were confirmed by Sanger sequencing and the c.3124_3133delAGCAATATTA mutation in *BRCA1* was also confirmed by restriction analysis ([Fig 3](#pone-0037432-g003){ref-type="fig"}). In the family of patient 1 (mutation c.5114_5117delTAAA) we found 10 clinically asymptomatic carriers ([Fig. 4](#pone-0037432-g004){ref-type="fig"}). The family with the c.2639_2640delTG mutation in *BRCA2* (patient 15) had a strong history of cancer, including laryngeal, gastric, lung and colon cancer in second- and third-degree relatives in the maternal branch ([Fig. 5](#pone-0037432-g005){ref-type="fig"}). In the family with the c.2805delAGAT mutation in *BRCA1* (patient 39), one first-degree relative had breast and colon cancer ([Fig. 6](#pone-0037432-g006){ref-type="fig"}). Interestingly, 3 of the 4 deleterious mutations have not been described previously. Likewise, we detected 16 genetic variants with unknown clinical significance (VUS), which included missense mutations and changes in intronic sequences ([Table 5](#pone-0037432-t005){ref-type="table"}). Four VUS were predicted to be potentially deleterious by *in silico* analyzes ([Table 5](#pone-0037432-t005){ref-type="table"}). Intronic variants that have been evaluated functionally through *in vitro* experiments by others were not present [@pone.0037432-Thry1]. No Ashkenazi founder mutations were found.

![Restriction analysis of the mutation c.3124_3133delAGCAATATTA found in patient 3.\
PCR products encompassing the mutation were digested with *Ssp*I (see [methods](#s2){ref-type="sec"}). The mutated allele has lost the *Ssp*I site and is not cleaved by the enzyme, while the wild-type allele is cut in two fragments. Lanes: 1) wild-type control PCR product not digested, 2) patient 11 PCR product not digested, 3) wild-type control PCR product digested, 4) patient 11 PCR product digested. Mut: mutated; Wt: wild-type.](pone.0037432.g003){#pone-0037432-g003}

![Genealogy of the family 1 carrier of the deleterious mutation c.5114_5117delTAAA in *BRCA2*.\
Index patient is denoted with an arrow. Individuals with cancer are represented with in dark circles or with dark squares; the type of cancer is indicated as follows: Bla: Bladder cancer; Br: Unilateral Breast Cancer; B-Br: Bilateral breast cancer. Current age or known ages of cancer diagnosis and decease are showed. Numbers inside the rhombi indicate quantity of relatives. Asymptomatic carriers are represented with a midline. Unaffected family members confirmed by the predictive molecular testing are shown with a W (wild type).](pone.0037432.g004){#pone-0037432-g004}

![Genealogy of the family 15 carrier of the deleterious mutation c.2639_2640delTG in *BRCA2*.\
Individuals with cancer are represented with dark circles or with dark squares; the type of cancer is indicated as follows: Br: unilateral breast cancer; Cr: colorectal cancer; NE: Not especified neoplasia; L: lung cancer; La: laryngeal cancer; Ga: gastric cancer. Index patient is denoted with an arrow. Current age or known ages of cancer diagnosis and decease are showed. Numbers inside the rhombi indicate quantity of first-degree relatives. Asymptomatic carriers are represented with a midline.](pone.0037432.g005){#pone-0037432-g005}

![Genealogy of the family 39 carrier of the deleterious mutation c.2805_2808delAGAT in *BRCA1*.\
Index patient is denoted with an arrow. Individuals with cancer are represented in dark; the type of cancer is indicated as follows: Br: unilateral breast cancer; Cr: colorectal cancer. Current age or known ages of cancer diagnosis and decease are showed. Numbers inside the rhombi indicate quantity of relatives.](pone.0037432.g006){#pone-0037432-g006}

10.1371/journal.pone.0037432.t002

###### Clinical features of the patients with *BRCA* mutations.

![](pone.0037432.t002){#pone-0037432-t002-2}

  Sample        Age (years)             Cancer Type              Age diagnosis (years)   Familial cancer history               Tumor Histological Features                Other Tumor Features [a](#nt103){ref-type="table-fn"}
  ------------ ------------- ---------------------------------- ----------------------- ------------------------- ----------------------------------------------------- ----------------------------------------------------------
  Patient 1         31                 Breast cancer                      31                       Yes                            Canalicular carcinoma                        ER positive, PR positive, Her2/neu positive
  Patient 3         42                 Ovarian cancer                     33                       No                         Ovarian serous adenocarcinoma                                    Not reported
                                  Unilateral Breast cancer                38                                                      Canalicular carcinoma                                      Triple negative
  Patient 15        37                 Ovarian cancer                     24                       Yes                        Ovarian serous adenocarcinoma                                    Not reported
                              Unilateral breast cancer (right)            37                                       Canalicular carcinoma, brisk lymphocytic infiltrate   ER positive, PR positive and Her2/neu negative Ki-67: 5%
  Patient 39        44            Bilateral breast cancer                 27                       Yes                            Canalicular carcinoma                                      Triple negative

ER  =  estrogen receptor; PR  =  progesterone receptor; HER2/neu  =  human epidermal growth factor receptor 2; Ki-67 =  antigen KI 67.

10.1371/journal.pone.0037432.t003

###### Clinical and familial features of the patients included in the study.

![](pone.0037432.t003){#pone-0037432-t003-3}

  ------------ ------------- -------- ------------------------------------------------ ----------------------------------------------------- ------------------------------------- ----------------------------------------- ----------------------------- ---------------------------- ------------------------------------------------------------- ------------------------- -----------------------------------
  Sample        Age (years)   Gender                    Cancer Type                                 Tumor Histological Features                      Other Tumor Features                    Age diagnosis (years)              Familial cancer history     Family members with cancer                                                                                          
                                                                                                                                                                                                                                                                      Number                                     Tumor type                                    Degree            Youngest age at diagnosis (years)
  Patient 1         31        Female                   Breast cancer                                   Canalicular carcinoma                    ER (+), PR (+) and Her2/neu (+)                       31                                  Yes                           5                        Bilateral BC, Unilateral BC Bladder cancer            1^st^, 2^nd^ and 3^rd^                   22
  Patient 2         35        Female              Unilateral Breast cancer                             Canalicular carcinoma                    ER (+), PR (+) and Her2/neu (−)                       30                                  Yes                           5                             Breast cancer. Colorectal cancer                     1^st^ and 2^nd^                      36
  Patient 3         42        Female                   Ovarian cancer                              Ovarian serous adenocarcinoma                         Not reported                                 33                                  No                                                                                                                                    
                                                  Unilateral Breast cancer                             Canalicular carcinoma                            Triple negative                               38                                                                                                                                                                        
  Patient 4         40        Female              Unilateral breast cancer                        In situ, canalicular carcinoma                ER (+), PR (+) and Her2/neu (−)                       38                                  Yes                           3                                       Breast cancer                              1^st^ and 2^nd^                      42
  Patient 5         64        Female              Unilateral breast cancer                             Canalicular carcinoma                            ER (+), PR (+)                                63                                  Yes                           2                                       Breast cancer                                   1^st^                           51
  Patient 6         66        Female              Unilateral breast cancer                             Canalicular carcinoma                            ER (+), PR (+)                                53                                  Yes                           10               Breast cancer. Ovarian cancer. Lymphoma. Intestinal cancer.   1^st^, 2^nd^ and 3^rd^.                  40
  Patient 7         29        Female              Unilateral breast cancer                             Canalicular carcinoma                            Triple negative                               28                                  Yes                           5                     Breast, pancreatic, colorectal and bladder cancer                 2^nd^                           47
  Patient 8         48        Female                   Breast cancer                                   Canalicular carcinoma                                  NA                                      47                                  Yes                           2                              Breast cancer. Ovarian cancer.                           1^st^                           41
  Patient 9         42        Female                   Breast cancer                                   Canalicular carcinoma                                  NA                                      41                                  Yes                           2                               Breast cancer. Ovarian cancer                           1^st^                           45
  Patient 10        68        Female                   Breast cancer                                   Canalicular carcinoma                            ER (+), PR (+)                                60                                  Yes                           13                  Breast, pancreatic, lung, liver and colorectal cancer          2^nd^ and 3^rd^                      44
  Patient 11        53        Female              Unilateral breast cancer                             Canalicular carcinoma                    ER (+), PR (+) and Her2/neu (−)                       49                                  Yes                           13                  Breast, pancreatic, lung, liver and colorectal cancer          2^nd^ and 3^rd^                      44
  Patient 12        68         Male    Unilateral breast cancer and colorectal cancer             Breast: Canalicular carcinoma.                              NA                    Colorectal cancer: 52 Breast cancer: 56               Yes                           1                                       Breast cancer                                   1^st^                           39
  Patient 13        62        Female              Bilateral breast cancer                        Multifocal, canalicular carcinoma              ER (+), PR (+) and Her2/neu (−)              1^st^: 48, 2^nd^: 60                         Yes                           5                              Breast, ovarian and skin cancer                     1^st^ and 2^nd^                      36
  Patient 14        37        Female              Unilateral breast cancer                             Canalicular carcinoma                            Triple negative                               35                                  Yes                           6                            Breast, prostatic and renal cancer                    1^st^ and 2^nd^                      28
  Patient 15        37        Female                   Ovarian cancer                              Ovarian serous adenocarcinoma                         Not reported                                 24                                  Yes                           6                     Breast, laryngeal, lung, gastric and colorectal.             2^nd^ and 3^rd^                      28
                                              Unilateral breast cancer (right)          Canalicular carcinoma, brisk lymphocytic infiltrate     ER (+), PR (+) and Her2/neu (−)                       37                                                                                                                                                                        
  Patient 16        30        Female              Unilateral breast cancer                             Canalicular carcinoma                    ER (+), PR (+) and Her2/neu (−)                       28                                  Yes                           1                                   Abdominal cancer (NA)                               1^st^                           31
  Patient 17        33        Female              Unilateral breast cancer                             Canalicular carcinoma                    ER (+), PR (+) and Her2/neu (−)                       30                                  Yes                           1                                 Breast and ovarian cancer                             1^st^                           55
  Patient 18        42        Female              Bilateral breast cancer                              Canalicular carcinoma                     Triple negative (both tumors)                 1st: 34, 2nd: 39                           Yes                           1                                       Breast cancer                                   1^st^                           41
  Patient 19        39        Female              Unilateral breast cancer                             Canalicular carcinoma                            Triple negative                               36                                  Yes                           7                                       Breast cancer                          1^st^, 2^nd^ and 3^rd^                \<40 (NA)
  Patient 20        65         Male               Unilateral breast cancer                             Lobulillar carcinoma                   Triple negative, androgen negative                      63                                  Yes                           1                                      Ovarian cancer                                   1^st^                           44
  Patient 21        28        Female              Unilateral breast cancer                             Canalicular carcinoma                            Triple negative                               27                                  Yes                           2                        Laringeal cancer and abdominal caáncer (NA)                    2^nd^                           50
  Patient 22        35        Female              Unilateral breast cancer                             Canalicular carcinoma                            Triple negative                               32                                  Yes                           2                                     Prostatic cancer                                  2^nd^                           58
  Patient 23        33        Female              Unilateral breast cancer                             Canalicular carcinoma                    ER (+), PR (+) and Her2/neu (+)                       32                      NA (no contact with family)               NA                                           NA                                          NA                             \-
  Patient¶24        58        Female              Unilateral breast cancer                             Canalicular carcinoma                    ER (−), PR (−) and Her2/neu (+)                       56                                  Yes                           2                               Breast and colorectal cancer                            1^st^                           33
  Patient 25        48        Female              Unilateral breast cancer                             Canalicular carcinoma                                  NA                                      37                                  Yes                           2                                 Breast and gastric cancer                             2^nd^                           40
  Patient 26        31        Female              Unilateral breast cancer                             Canalicular carcinoma                    ER (+), PR (+) and Her2/neu (+)                       29                                  Yes                           4                           Skin, laringeal and intestinal cancer                  2^nd^ and 3^rd^                      35
  Patient 27        35        Female              Unilateral breast cancer                             Canalicular carcinoma                            Triple negative                               33                                  Yes                           1                                   Abdominal cancer (NA)                               2^nd^                           30
  Patient 28        30        Female              Unilateral breast cancer                             Canalicular carcinoma                            Triple negative                               25                                  Yes                           4                             Brest, gastric and thyroid cancer                         2^nd^                           30
  Patient 29        53        Female              Bilateral breast cancer                              Canalicular carcinoma                            Triple negative                               52                                  Yes                           5                   Bilateral and unilateral breast cancer. Liver cancer       1^st^, 2^nd^ and 3^rd^                   40
  Patient 30        25        Female              Unilateral breast cancer                             Canalicular carcinoma                    ER (+), PR (+) and Her2/neu (+)                       24                                  Yes                           10                             Breast cancer. Prostatic cancer                     1^st^ and 2^nd^                      41
  Patient 31        41        Female              Unilateral breast cancer                       Multifocal, canalicular carcinoma              ER (+), PR (+) and Her2/neu (−)                       39                                  Yes                           5                                 Breast and gastric cancer                        1^st^ and 2^nd^                      38
  Patient 32        46        Female                   Ovarian cancer                                 Endometrioid carcinoma                             Not reported                                 42                                  Yes                           4                               Breast cancer. Ovarian cancer                      1^st^ and 2^nd^                      30
  Patient 33        61        Female              Unilateral breast cancer                             Canalicular carcinoma                    ER (+), PR (+) and Her2/neu (−)                       56                                  Yes                           3                         Breast cancer (Father with breast cancer)                1^st^ and 2^nd^                      31
  Patient 34        28        Female              Unilateral breast cancer                             Canalicular carcinoma                    ER (+), PR (+) and Her2/neu (−)                       27                      NA (no contact with family)               NA                                           NA                                          NA                             \-
  Patient 35        52        Female          Unilateral breast cancer + NF-1                          Canalicular carcinoma                  ER positive, PR (+)and Her2/neu (−)                     46                                  Yes                           2                                Breast cancer. Liver cancer                            1^st^                           49
  Patient 36        60        Female          Unilateral breast cancer + NF-1                          Canalicular carcinoma                            Triple negative                               49                                  Yes                           2                                Breast cancer. Liver cancer                            1^st^                           46
  Patient 37        40        Female              Unilateral breast cancer                             Canalicular carcinoma                            Triple negative                               36                                  No                            \-                                           \-                                          \-                             \-
  Patient 38        39        Female              Unilateral breast cancer                             Canalicular carcinoma                            Triple negative                               35                                  No                            \-                                           \-                                          \-                             \-
  Patient 39        44        Female              Bilateral breast cancer                              Canalicular carcinoma                            Triple negative                        1st: 27, 2nd: 33                           Yes                           1                               Breast and colorectal cancer                            1^st^                           54
  ------------ ------------- -------- ------------------------------------------------ ----------------------------------------------------- ------------------------------------- ----------------------------------------- ----------------------------- ---------------------------- ------------------------------------------------------------- ------------------------- -----------------------------------

ER  =  estrogen receptor; PR  =  progesterone receptor; HER2/neu  =  human epidermal growth factor receptor 2.

NA: Information not available.

NF-1: Neurofibromatosis type 1

10.1371/journal.pone.0037432.t004

###### Detection of BRCA deleterious mutations in patients.

![](pone.0037432.t004){#pone-0037432-t004-4}

  Sample         Gene             Mutation           Type of mutation   Position (aa)   Stop position (aa)   Coverage[1](#nt107){ref-type="table-fn"}   Clinical relevance   BIC reported           References
  ------------ --------- -------------------------- ------------------ --------------- -------------------- ------------------------------------------ -------------------- -------------- -----------------------------
  Patient 3     *BRCA1*   c.3124_3133delAGCAATATTA          F               1042               1047                             77                             Yes                No               Not reported
  Patient 39    *BRCA1*     c.2805_2808del AGAT             F                935               998                              21                             Yes                No               Not reported
  Patient 1     *BRCA2*      c.5114_5117delTAAA             F               1705               1710                             70                             Yes               Yes        [@pone.0037432-DezGilbert1]
  Patient 15    *BRCA2*       c.2639_2640delTG              F                880               888                              29                             Yes                No               Not reported

Number of reads per nucleotide.

Types of mutations: F: frameshift; S: stop.

10.1371/journal.pone.0037432.t005

###### Variants of uncertain significance (VUS) detected in patients.

![](pone.0037432.t005){#pone-0037432-t005-5}

  Patient                                    Gene     Localization        Variant        Type of Mutation1[1](#nt109){ref-type="table-fn"}   Clinical Relevance   PolyPhen2 prediction[2](#nt110){ref-type="table-fn"}   BIC Reported
  ---------------------------------------- --------- -------------- ------------------- --------------------------------------------------- -------------------- ------------------------------------------------------ --------------
  2, 26, 31, 33                             *BRCA2*     Exon 27          p.I3412V                                M                                  VUS                                    B                                 Yes
  5, 26, 30                                 *BRCA1*     Exon 11           p.Q356R                                M                                  VUS                                    PD                                Yes
  6                                         *BRCA2*     Exon 11          p.H1561N                                M                                  VUS                                    PD                                Yes
  6                                         *BRCA2*     Exon 11          p.V2138F                                M                                  VUS                                    B                                 Yes
  7                                         *BRCA1*     Exon 11          p.S1040N                                M                                  VUS                                    B                                 Yes
  10, 13, 14, 18, 26, 27, 28, 30, 31, 39    *BRCA1*     Intron 1         c.−19T\>C                              Ts                                  VUS                                    \-                                Yes
  10, 11, 17                                *BRCA1*     Exon 11          p.K1183R                                M                              Not reported                               B                                  No
  10, 15, 16, 17                            *BRCA2*    Intron 11     c.6841+80del TTAA                           D                                  VUS                                    \-                                Yes
  12, 17                                    *BRCA1*     Intron 7       c.442−34C\>T                             Ts                                  VUS                                    \-                                Yes
  12                                        *BRCA1*     Exon 11          p.D1344G                                M                                  VUS                                    PD                                Yes
  16                                        *BRCA2*     Exon 11          p.T1915M                                M                                  VUS                                    B                                 Yes
  17                                        *BRCA1*     Exon 12          p.K1489E                                M                              Not reported                               B                                  No
  18, 20, 39                                *BRCA1*    Intron 12      c.4097−141A\>C                            Tv                                  VUS                                    \-                                Yes
  18                                        *BRCA1*    Intron 14       c.4485−64C\>G                            Tv                                  VUS                                    \-                                Yes
  19, 20, 21, 24, 27, 28, 31                *BRCA2*     Exon 15          p.I2490T                                M                                  VUS                                    B                                 Yes
  21                                        *BRCA1*     Exon 23          p.V1810V                                S                              Not reported                               B                                  No
  30                                        *BRCA1*     Exon 23          p.V1804D                                M                                  VUS                                    B                                 Yes
  30                                        *BRCA2*     Exon 11          p.S1733S                                S                                  VUS                                    B                                 Yes
  30                                        *BRCA2*     Exon 21           K2950N                                 M                                  VUS                                    PD                                Yes

D: deletion; M: missense mutation; S: synonimous mutation; Ts: transition; Tv: transvertion.

B: benign; PD: probably damaging.

Discussion {#s4}
==========

Molecular genetic testing of germline mutations in BRCA genes is not common in public institutions in Latin America due to its high costs and limitations in infrastructure. Current protocols for BRCA mutation detection are time consuming and laborious, which makes difficult their implementation in developing countries. Also, the polymorphic nature of BRCA genes, their long size and lack of hot mutation spots highlight the necessity to implement new high throughput diagnostic methodologies. Almost 10% of breast cancer is associated to hereditary mutations [@pone.0037432-Szabo1]. Likewise, the lifetime risk of developing breast cancer is been reported as high as 80% and 50% for *BRCA1* and *BRCA2* mutation carriers, respectively; although it varies between different populations and ethnicities [@pone.0037432-Easton1], [@pone.0037432-Chen1]. In this light, BRCA genetic testing is of major diagnostic relevance not only because it provides a clinical preventive approach to family members before the development of cancer, but also can imply novel treatment strategies for affected patients, such as the use of poly-(ADP--ribose) polymerase inhibitors [@pone.0037432-Kwon1]--[@pone.0037432-Tutt1]. Additionally, BRCA genetic tests are central for the determination of founder mutations, which are frequent deleterious variants that can be screened in the population in first-line directed studies to reduce costs and accelerate diagnosis [@pone.0037432-Ferla1], [@pone.0037432-Zhang1]. In the Mexican population no founder mutations have been described.

In these work we analysed BRCA full exome and splice site mutations by massive parallel pyrosequencing. In the evaluation of the method, we found all the mutations present in previously characterized positive controls; negative controls showed no variants. The coverage of the sequences for the mutations varied from 41 to 485X, with quality scores of 20--40 in 95% of the reads throughout all the exonic and splice sites regions. These results led us to evaluate mutations in patients with hereditary breast and ovarian cancer syndrome and in patients with clinical features suggestive for BRCA deleterious mutations. In these analyses we found 4 (10.2%) BRCA mutations in the 39 patients, which is very similar to the prevalence reported by other studies of families with hereditary cancer in Latin America [@pone.0037432-VidalMilln1], [@pone.0037432-RuizFlores1], [@pone.0037432-GutirrezEspeleta1]. All the mutations found in these patients have not been previously described and are not reported in the Breast Cancer Information core (BIC) and NCBI variant databases, which is in concordance with the polymorphic nature of these genes [@pone.0037432-Lips1]. Interestingly, one of these mutations was in a patient with no history of familial cancer, but with strong suggestive clinical manifestations of a BRCA mutation, such as early-onset breast cancer [@pone.0037432-Musolino1]. This result highlights the necessity to extend the screening for BRCA mutations also to candidate patients with no history of familial cancer, which is in concordance with reports that described that 30--50% of BRCA mutation carriers have not family history of breast and ovarian cancer [@pone.0037432-deSanjos1], [@pone.0037432-Mller1]. Remarkably, we found 10 clinically asymptomatic *BRCA2* mutation (c.5114_5117delTAAA) carriers in family 1, which reflects the incomplete penetrance associated with different BRCA mutations and that there are other risk factors associated with the penetrance of BRCA mutations [@pone.0037432-Thompson1]--[@pone.0037432-Nkondjock1]. In this study we used massive parallel pyrosequencing because its capacity to screen the whole exonic and splice site regions of *BRCA1* and *BRCA2* in up to 8 samples per run and its high depth of sequence, which provides more sensitivity for mutation detection than conventional Sanger sequencing and makes this strategy cost-effective [@pone.0037432-Gilles1]. Also, these advantages offer great benefit to the diagnostic scenario, comparing to other methods. However, this technology has intrinsic limitations, namely the detection of whole exon deletions and the identification of mutations in homopolymeric tracts longer than 6 bases. Since the frequency of exon deletion and large genomic rearrangements is population-dependent and has been described as 1--30% in BRCA-associated cancers, it is determinant to further evaluate putative BRCA mutation-negative samples by complementary methods, such as Multiplex Ligation-dependent Probe Amplification analysis [@pone.0037432-Hofmann1]--[@pone.0037432-Ewald1]. Also the evaluation of homopolymeric tract variants, which comprise 12 stretches longer than 6 nt in the *BRCA1* and *BRCA2* coding sequences, should be assessed with alternative methods such as high-resolution-melting-curve-analysis [@pone.0037432-DeLeeneer2]. When negative, these analyzes would rule out the BRCA etiology of the tumor. Thus, in these patients with clear familial history of cancer, the evaluation of mutations in other genes, like *PALB2*, *CHEK2* and *RAD51C*, should also be considered [@pone.0037432-Blanco1]--[@pone.0037432-Vuorela1]. This could be the case of some of the families of this study, in which we screened 35 patients with a clear familial history of cancer, but we only found 3 patients with mutations in BRCA. Additionally, the presence of VUS could be related to pathogenic effects at the level of mRNA processing, stability, translation and protein function, as has been described in *BRCA1* and other genes [@pone.0037432-Liu1]--[@pone.0037432-Duan1]. The effect of VUS is subject of great interest as their presence exceeds mutations in patients with familial cancer; however, their functional evaluation is far from being a common diagnostic practice. In this regard, the functional evaluation of some VUS in the BRCA genes has showed that single nucleotide variations in introns can influence mRNA processing, producing exon skipping and aberrant out of frame mRNA forms [@pone.0037432-Thry1]. We found 16 not previously described VUS, especially in patients without deleterious BRCA variants and 4 were predicted to be pathogenic by computational analyses. Functional studies must be undertaken to evaluate their effects. In this concern, we foresee that new routine methods will soon be accessible to determine the molecular and pathological relevance of these variants.

In summary, this work illustrates how hole exonic and splice site massive parallel pyrosequencing can be used as a diagnostic strategy to determine BRCA mutations. Its use circumvents the laborious and time-consuming efforts of the current methodologies. With this technology we found 4 mutations and 16 VUS in our series of patients with familial cancer, which highlights the relevance of this approach as a diagnostic tool and suggests it could be used as a routine practice in public health institutions.
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